Skip to main content

Vaccines: Manufacturing Industries

Question for Department for Business, Energy and Industrial Strategy

UIN 148771, tabled on 3 February 2021

To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to increase the UK’s long-term vaccine manufacturing capacity.

Answered on

12 February 2021

The Government has invested over £300 million to secure and scale up the UK’s manufacturing capabilities to be able to respond to the pandemic. This includes:

a) Facilities that have come online:

  • £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;
  • £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;
  • £65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine; and
  • Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the University of Oxford / AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer term UK capacity:

  • £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire; and
  • £127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.

Answered by

Department for Business, Energy and Industrial Strategy